In 2004, a systematic review on the metabolic effects of sibutramine28 was published without any mention of arterial pressure (outcomes: weight reduction and maintenance of weight loss; effects relating to glycemic control and type 2 diabetes; effects on lipids, non-alcoholic fatty liver disease, serum uric acid levels, adipocytokines and C-reactive protein; plasma fibrinogen levels; polycystic ovary syndrome; and plasma homocysteine levels). Here, CRP is linked to metabolic dysfunction-associated steatotic liver disease.